In contrast, type II tumours, including high-grade serous and undifferentiated carcinomas characterised by p53 mutations and overexpression/amplification of HER-2/neu and AKT2, tend to show a highly aggressive behaviour (Shih and Kurman, 2004; Bell, 2005). Here, TP53 is linked to undifferentiated carcinoma.